1. Market Research
  2. > Pharmaceutical Market Trends
Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class ; Route of Administration ; Distribution Channel ; and Geography

Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class ; Route of Administration ; Distribution Channel ; and Geography

  • June 2020
  • 180 pages
  • ID: 5932661
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

The global chronic cough market is expected to reach US$ 9,854.8 million by 2027 from US$ 5,430.0 million in 2019; it is estimated to grow at a CAGR of 7.8% from 2020 to 2027. The market growth is attributed to the key factors such as increasing rising incidences of chronic cough and growing product developments to treat chronic cough. On the other hand, product recall is the major factor, which is likely to affect the market growth negatively during the forecast period.

The developments in the pharmaceutical and biopharmaceutical industry for the drugs that can treat chronic cough are likely to lead the market growth.Additionally, there is a rise in the numbers of pharmaceutical companies across the world.

Several startups across the globe are involved in the product development for chronic cough. For instance, in May 2020, BELLUS Health Inc., a biopharmaceutical company, has developed novel therapeutics for the chronic cough and other hypersensitization-related disorders. The company is constantly engaged in product development and has recently conducted a virtual key opinion leader (KOL) meeting to discuss the developments regarding chronic cough on 27 May 2020. Specifically, the meeting covered the developmental aspects regarding phase 2 RELIEF trial of BLU-5937 in chronic refractory cough. The company is looking forward to releasing data of clinical trials for RELIEF in June or July 2020.

The universities are engaged in research work for the development of new drugs to cure chronic cough.For instance, in February 2020, the results of two clinical trials phases for a new drug, Gefapixant were releases.

The researchers at the University of Manchester developed Gefapixant. The pharmaceutical market leader Merck & Co., Inc. (MSD) funded the clinical trials, in which the results showed that a dose of 7.5 mg reduced the cough by 52%, 20mg by 52%, and 50mg by 67% from baseline. The drug targets P2X3 receptors in the nerves that control coughing. Therefore, the developments by the pharmaceutical companies to treat chronic cough are likely to support the market growth during the forecast period.
The global chronic cough market is segmented by drug class, route of administration, and distribution channel.Based on drug class, the market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class.

The combination drug segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR during the forecast period.Based on route of administration, the chronic cough market has been segmented into oral, injections, inhalation, and other route of administration.

The oral segment held the largest share of the market in 2019; whereas, the inhalation segment is estimated to register the highest CAGR during the forecast period.Based on distribution channel, the chronic cough market has been segmented into hospital pharmacy, online pharmacy, and retail pharmacy.

The hospital pharmacy segment held largest market share in 2019. However, online pharmacy is expected to grow at a fastest CAGR during forecast period.

The American College of Chest Physicians, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Dubai Health Authority, European Respiratory Society, and Japanese Respiratory Society are among the essential secondary sources refereed to while preparing this report.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on